keyword
MENU ▼
Read by QxMD icon Read
search

Glulisine

keyword
https://www.readbyqxmd.com/read/29623593/efficacy-and-safety-of-rapid-acting-insulin-analogs-in-special-populations-with-type-1-diabetes-or-gestational-diabetes-systematic-review-and-meta-analysis
#1
REVIEW
Kirsten Nørgaard, Nithya Sukumar, Snorri B Rafnsson, Ponnusamy Saravanan
INTRODUCTION: To assess the efficacy and safety of three available rapid-acting insulin analogs (insulins lispro, aspart and glulisine, respectively) in pregnant women, children/adolescents and people using continuous subcutaneous insulin infusion (CSII) with type 1 diabetes. METHODS: PubMed, EMBASE and Cochrane Reviews were searched electronically, and their bibliographies examined to identify suitable studies for review and inclusion in a meta-analysis. Eligible studies were randomized controlled trials that reported data on relevant clinical outcomes...
April 5, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29596514/characterisation-of-insulin-analogues-therapeutically-available-to-patients
#2
Gary G Adams, Andrew Meal, Paul S Morgan, Qushmua E Alzahrani, Hanne Zobel, Ryan Lithgo, M Samil Kok, David T M Besong, Shahwar I Jiwani, Simon Ballance, Stephen E Harding, Naomi Chayen, Richard B Gillis
The structure and function of clinical dosage insulin and its analogues were assessed. This included 'native insulins' (human recombinant, bovine, porcine), 'fast-acting analogues' (aspart, glulisine, lispro) and 'slow-acting analogues' (glargine, detemir, degludec). Analytical ultracentrifugation, both sedimentation velocity and equilibrium experiments, were employed to yield distributions of both molar mass and sedimentation coefficient of all nine insulins. Size exclusion chromatography, coupled to multi-angle light scattering, was also used to explore the function of these analogues...
2018: PloS One
https://www.readbyqxmd.com/read/29462782/utilizing-elisa-plate-based-immunopurification-and-liquid-chromatography-tandem-mass-spectrometry-for-the-urinary-detection-of-short-and-long-acting-human-insulin-analogues
#3
Péter Judák, Peter Van Eenoo, Koen Deventer
The measurement of human insulin and its synthetic analogues in biological matrices has become increasingly important not only in clinical fields but also in doping control. The use of insulin and its analogues have been included in the list of prohibited substances published by the World Anti-Doping Agency (WADA). This study describes a qualitative method for detection of insulin analogues (lispro, aspart, glulisine, glargine, degludec, detemir) in human urine. The sample preparation consists of a preconcentration step using ultrafiltration followed by an immunoaffinity extraction with an antibody precoated ELISA plate...
February 12, 2018: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/29381818/role-of-omalizumab-in-insulin-hypersensitivity-a-case-report-and-review-of-the-literature
#4
S Mishra, L Connors, B Tugwell
BACKGROUND: Insulin allergy is a rare yet severe side effect of exogenous insulin use. Management typically involves use of alternative antihyperglycaemic agents, symptom control with antihistamines, use of different insulin formulations, and induction of tolerance with incremental doses of insulin. This treatment regimen is not always successful, and the use of omalizumab, an anti-IgE monoclonal antibody, has been used to induce tolerance to insulin. CASE REPORT: G...
January 30, 2018: Diabetic Medicine: a Journal of the British Diabetic Association
https://www.readbyqxmd.com/read/29341461/effect-of-immediate-and-prolonged-glp-1-receptor-agonist-administration-on-uric-acid-and-kidney-clearance-post-hoc-analyses-of-four-clinical-trials
#5
Lennart Tonneijck, Marcel H A Muskiet, Mark M Smits, Petter Bjornstad, Mark H H Kramer, Michaela Diamant, Ewout J Hoorn, Jaap A Joles, Daniël H van Raalte
AIMS: To determine the effects of glucagon-like peptide (GLP)-1 receptor agonists (RA) on uric acid (UA) levels and kidney UA clearance. MATERIAL AND METHODS: This study involved post-hoc analyses of 4 controlled clinical trials, which assessed actions of GLP-1RA administration on kidney physiology. The immediate effects of GLP-1RA exenatide infusion vs placebo were determined in 9 healthy overweight men (Study-A) and in 52 overweight T2DM patients (Study-B). The effects of 12 weeks of long-acting GLP-1RA liraglutide vs placebo in 36 overweight T2DM patients (Study-C) and of 8 weeks of short-acting GLP-1RA lixisenatide vs once-daily titrated insulin glulisine in 35 overweight T2DM patients (Study-D) were also examined...
January 17, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29316176/effect-of-prandial-treatment-timing-adjustment-based-on-continuous-glucose-monitoring-in-patients-with-type-2-diabetes-uncontrolled-with-once-daily-basal-insulin-a-randomized-phase-iv-study
#6
Jacob Ilany, Hamad Bhandari, Dan Nabriski, Yoel Toledano, Noa Konvalina, Ohad Cohen
AIMS: To evaluate the glycaemic control achieved by prandial once-daily insulin glulisine injection timing adjustment, based on a continuous glucose monitoring sensor, in comparison to once-daily insulin glulisine injection before breakfast in patients with type 2 diabetes who are uncontrolled with once-daily basal insulin glargine. MATERIALS AND METHODS: This was a 24-week open-label, randomized, controlled, multicentre trial. At the end of an 8-week period of basal insulin optimization, patients with HbA1c ≥ 7...
January 8, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28762200/rapid-acting-and-human-insulins-hexamer-dissociation-kinetics-upon-dilution-of-the-pharmaceutical-formulation
#7
Klaus Gast, Anja Schüler, Martin Wolff, Anja Thalhammer, Harald Berchtold, Norbert Nagel, Gudrun Lenherr, Gerrit Hauck, Robert Seckler
PURPOSE: Comparison of the dissociation kinetics of rapid-acting insulins lispro, aspart, glulisine and human insulin under physiologically relevant conditions. METHODS: Dissociation kinetics after dilution were monitored directly in terms of the average molecular mass using combined static and dynamic light scattering. Changes in tertiary structure were detected by near-UV circular dichroism. RESULTS: Glulisine forms compact hexamers in formulation even in the absence of Zn(2+)...
November 2017: Pharmaceutical Research
https://www.readbyqxmd.com/read/28702259/clinical-effects-cardiovascular-and-renal-outcomes-associated-with-rapid-acting-insulin-analogs-among-individuals-with-type-2-diabetes-a-nation-wide-observational-cohort-study
#8
Ann-Marie Svensson, Mervete Miftaraj, Stefan Franzén, Björn Eliasson
BACKGROUND: Rapid-acting insulin analogs (RAIs) have not been examined for long-term safety in randomized clinical trials. We performed a nationwide longitudinal cohort study among individuals with type 2 diabetes (T2DM) to address cardiovascular safety and mortality among users of lispro, aspart and glulisine insulins. METHODS: We used four national registers, following patients previously not treated with RAI but with continuous use of RAIs in 2005-2014 up to 6...
2017: Clinical Diabetes and Endocrinology
https://www.readbyqxmd.com/read/28544684/insulin-glulisine-for-continuous-subcutaneous-insulin-infusion-in-pediatric-type-1-diabetes
#9
Tatsuhiko Urakami, Yusuke Mine, Masako Aoki, Misako Okuno, Junichi Suzuki
We evaluated the efficacy and safety of insulin glulisine (GLU) used for continuous s.c. insulin infusion (CSII) in 20 children with type 1 diabetes after 1 year of GLU treatment. There were no significant differences in mean plasma glucose before breakfast and before dinner between before and after using GLU, but the levels after breakfast and after dinner significantly improved, from 192.5 ± 31.7 to 162.0 ± 27.3 mg/dL for breakfast, and from 191.1 ± 33.3 to 161.1 ± 24.5 mg/dL for dinner (P < 0...
May 2017: Pediatrics International: Official Journal of the Japan Pediatric Society
https://www.readbyqxmd.com/read/28449402/postprandial-renal-haemodynamic-effect-of-lixisenatide-vs-once-daily-insulin-glulisine-in-patients-with-type-2-diabetes-on-insulin-glargine-an-8-week-randomised-open-label-trial
#10
Lennart Tonneijck, Marcel H A Muskiet, Mark M Smits, Trynke Hoekstra, Mark H H Kramer, A H Jan Danser, Michaela Diamant, Jaap A Joles, Daniël H van Raalte
AIM: To determine whether lixisenatide, a prandial short-acting glucagon-like peptide receptor agonist (GLP-1RA), ameliorates postprandial glomerular hyperfiltration in patients with type 2 diabetes mellitus (T2DM) compared with insulin-glulisine (iGlu). METHODS: Postprandial renal haemodynamic effects of 8-week treatment with lixisenatide 20 µg vs once-daily titrated iGlu were measured in 35 overweight patients with T2DM inadequately controlled on insulin-glargine, with or without metformin [mean ± SD age 62 ± 7 years, HbA1c 8...
December 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28371461/comparison-of-morning-basal-1-bolus-insulin-therapy-insulin-glulisine-insulin-glargine-300-u-ml-vs-insulin-lispro-insulin-glargine-biosimilar-using-continuous-glucose-monitoring-a-randomized-crossover-study
#11
Soichi Takeishi, Hiroki Tsuboi, Shodo Takekoshi
INTRODUCTION: We compared the effects of morning administration of insulin glulisine + insulin glargine 300 U/mL (G + G300) with that of insulin lispro + insulin glargine biosimilar (L + GB). MATERIALS AND METHODS: A total of 30 patients with type 2 diabetes who wore a continuous glucose monitoring device on admission after glucose levels were stabilized by morning long-acting and ultra-rapid-acting insulins were randomly allocated to groups who received G + G300 on days 1 and 2, and the same dose L + GB on days 3 and 4, or vice versa...
January 2018: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/28357772/switch-to-combined-glp1-receptor-agonist-lixisenatide-with-basal-insulin-glargine-in-poorly-controlled-t2dm-patients-with-premixed-insulin-therapy-a-clinical-observation-and-pilot-study-in-nine-patients
#12
Jürgen Harreiter, Lana Kosi-Trebotic, Albert Lukas, Peter Wolf, Yvonne Winhofer, Anton Luger, Alexandra Kautzky-Willer, Michael R Krebs
INTRODUCTION: To prove the feasibility and safety of a conversion to once-daily injected GLP1 agonist (lixisenatide) and long-acting basal insulin analogue (glargine) in patients with T2DM and poorly controlled glycemia previously treated with multiple injections of premixed insulins (iPremix) in an outpatient setting. METHODS: Nine patients with T2DM currently receiving iPremix formulations and poor glycemic control were switched to once-daily injected lixisenatide (Lixi) and basal insulin analogue glargine (iGlar) for a 12-week period...
June 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28314656/safety-and-efficacy-of-a-basal-plus-regimen-with-insulin-glargine-and-insulin-glulisine-for-elderly-patients-with-high-cardiovascular-risk-and-type-2-diabetes-mellitus
#13
R Gómez-Huelgas, J Sabán-Ruiz, F J García-Román, N Quintela-Fernández, J M Seguí-Ripoll, M V Bonilla-Hernández, G Romero-Meliá
OBJECTIVES: To assess the safety and efficacy of a basal-plus (BP) regimen with insulin glargine (as basal insulin) and insulin glulisine (as prandial insulin) with the main meal for elderly patients with type 2 diabetes mellitus (DM2) and high cardiovascular risk, following standard clinical practice. PATIENTS AND METHODS: An observational, retrospective study was conducted in 21 centres of internal medicine in Spain. The study included patients aged 65 years or older with DM2, undergoing treatment with a BP regimen for 4 to 12 months before inclusion in the study and a diagnosis of cardiovascular disease or high cardiovascular risk...
March 14, 2017: Revista Clínica Española
https://www.readbyqxmd.com/read/28271733/evaluating-drug-cost-per-responder-and-number-needed-to-treat-associated-with-lixisenatide-on-top-of-glargine-when-compared-to-rapid-acting-insulin-intensification-regimens-on-top-of-glargine-in-patients-with-type-2-diabetes-in-the-uk-italy-and-spain
#14
Marion Afonso, Fay Ryan, Ashley Pitcher, Elisheva Lew
OBJECTIVES: This study investigated the cost per responder and number needed to treat (NNT) in type 2 diabetes mellitus (T2DM) patients for lixisenatide compared to insulin intensification regimens using composite endpoints in the UK, Italy, and Spain. METHODS: Efficacy and safety outcomes were obtained from GetGoal Duo-2, a 26-week phase 3 trial comparing lixisenatide vs insulin glulisine (IG) once daily (QD) and three times daily (TID). Response at week 26 was extrapolated to 52 weeks, assuming a maintained treatment effect, based on long-term evidence in other T2DM populations...
March 29, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28133970/lixisenatide-a-new-daily-glp-1-agonist-for-type-2-diabetes-management
#15
REVIEW
Delilah McCarty, Megan Coleman, Cassie L Boland
OBJECTIVE: To review the pharmacology, pharmacokinetics, efficacy, and safety of the glucagon-like peptide-1 receptor agonist (GLP-1RA), lixisenatide, in the treatment of type 2 diabetes mellitus. DATA SOURCES: A PubMed (1966-2016) search was conducted using the following keywords: lixisenatide, AVE0010, glucagon-like peptide-1 agonist, and type 2 diabetes. References were reviewed to identify additional sources. STUDY SELECTION AND DATA EXTRACTION: Articles written in English were included if they evaluated the pharmacology, pharmacokinetics, efficacy, or safety of lixisenatide in human subjects...
May 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28032423/comparison-of-the-impact-of-human-vs-analogue-insulins-on-glycosylated-haemoglobin-in-a-population-with-diabetes-mellitus
#16
Jorge Enrique Machado-Alba, Diego Alejandro Medina-Morales
AIMS: To compare the effect on metabolic control of treatment with conventional and analogue insulins for patients with diabetes mellitus. METHODS: Retrospective cohort study held in cities of Colombia (Pereira and Manizales). People insured by the paid healthcare system, who were diagnosed with diabetes mellitus type 1 and 2, and treated with conventional and analogue insulin for at least 6 months prior to the start of the study were sampled and followed up for 18 months...
December 2016: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/27517679/clinical-effects-and-safety-of-direct-acting-insulin-analogs-in-patients-with-type-1-diabetes-a-nation-wide-observational-cohort-study
#17
Vincent Lak, Ann-Marie Svensson, Mervete Miftaraj, Stefan Franzén, Björn Eliasson
INTRODUCTION: Studies comparing direct-acting insulin analogs (DAIs) in terms of effectiveness and long-term safety are scarce. Our aim was to explore these variables in clinical practice among patients with type 1 diabetes, including the elderly and those with renal impairment. METHODS: We linked four national registers in a population-based cohort study. Patients with type 1 diabetes and continuous use of all currently available DAIs (lispro, aspart, or glulisine) in 2005-2013 were monitored for up to 7...
September 2016: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/27390032/20-years-of-insulin-lispro-in-pediatric-type-1-diabetes-a-review-of-available-evidence
#18
REVIEW
Kevin Kaiserman, Heike Jung, Imane Benabbad, Beate Karges, Michel Polak, Myriam Rosilio
BACKGROUND: Insulin lispro, the first rapid-acting insulin analog, was developed 20 years ago and has been studied in multiple situations and various populations. OBJECTIVE: To review the literature on the use of insulin lispro in children, adolescents, and young adults. PATIENTS: Children, adolescents, and young adults with type-1-diabetes. METHODS: One hundred and twenty-two relevant publications, identified by a systematic (MEDLINE) and manual literature search, were reviewed...
March 2017: Pediatric Diabetes
https://www.readbyqxmd.com/read/27222510/prandial-options-to-advance-basal-insulin-glargine-therapy-testing-lixisenatide-plus-basal-insulin-versus-insulin-glulisine-either-as-basal-plus-or-basal-bolus-in-type-2-diabetes-the-getgoal-duo-2-trial
#19
RANDOMIZED CONTROLLED TRIAL
Julio Rosenstock, Bruno Guerci, Markolf Hanefeld, Sandro Gentile, Ronnie Aronson, Francisco J Tinahones, Christine Roy-Duval, Elisabeth Souhami, Marek Wardecki, Jenny Ye, Riccardo Perfetti, Simon Heller
OBJECTIVE: To provide evidence-based options on how to intensify basal insulin, we explored head-to-head prandial interventions in overweight patients with type 2 diabetes inadequately controlled on basal insulin glargine with or without 1-3 oral antidiabetic agents (OADs). RESEARCH DESIGN AND METHODS: Patients were randomized to lixisenatide once daily or insulin glulisine given once or thrice daily, added to glargine, with or without metformin, if HbA1c remained ≥7 to ≤9% (≥53 to ≤75 mmol/mol) after 12 weeks of glargine optimization with OADs other than metformin stopped at the start of optimization...
August 2016: Diabetes Care
https://www.readbyqxmd.com/read/27168767/access-to-medicines-for-diabetes-treatment-in-brazil-evaluation-of-health-has-no-price-program
#20
João Leopoldo Oliveira Araujo, Mariana Donato Pereira, Cristiane de Cássia Bergamaschi, Fernando de Sá Del Fiol, Luciane Cruz Lopes, Maria Inês de Toledo, Silvio Barberato-Filho
BACKGROUND: In 2011, private pharmacies associated to the Brazilian Ministry of Health provided patients with two types of insulin (regular human insulin and isophane insulin or NPH) and three oral antidiabetic medications (5 mg glibenclamide and 500 and 850 mg metformin) free of charge. The aim was to evaluate the impact of the "Health Has No Price" Program [Saúde Não Tem Preço (SNTP)] for access to diabetes treatment medicines in Brazil. METHODS: This longitudinal and observational study is based on the number of units of oral hypoglycemic agents, insulin and insulin analogues supplied in 55,000 private pharmacies from February 1, 2010 to January 31, 2012...
2016: Diabetology & Metabolic Syndrome
keyword
keyword
106075
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"